top of page
HiNgraft technology platform
Convert your cultured hematopoietic stem cells into highly-engrafting cells that readily integrate the bone marrow niche, largely outcompeting normal (HSC) and cancer stem cells (CSC) for niche occupancy.
Featured application: Using HiNgraft cell therapy in current cancer treatment scheme
HSC niche-hijacking/imitating cancers
acute myeloid leukemias, acute lymphoid leukemias, prostate cancer, glioblastoma...
In vitro modeling of the BM niche
BM organoid optimization, organoid-based HSC potency assay...
Hematopoietic niche repair/protection
Myelodysplastic syndromes, beta-thalassemia, chemotherapy-induced damage....
Improving HSC transplantation
Off-the-shelf universal HSC grafts, expansion & genetic modification of highly-engraftable HSC, toxicity-free conditioning...
Patent pending medication
Makes possible the regeneration of your immune system by increasing the output of blood cells from HSC:
in conditions of cytopenias (weak blood cell production)
after/during hematopoietic stem cell transplantation (increases graft success and immune reconstitution)
PROBLEM Although hematopoietic stem cell (HSC) transplantation has revolutionized the fields of oncology and immunodeficiency, many aspects remain problematic, including engraftment failure and slow/insufficient generation of mature blood cell types, inevitably leading to death of the patient, or serious health complications with prolonged hospitalization. There exists no viable alternative (oral medication) to increase the engraftment of transplanted HSC and to speed up immune reconstitution.
OUR SOLUTION We have discovered a family of medicinal compounds, that when administered to the organism, exert their specific action on HSC, altering their function to allow for better engraftment and accelerated recovery of the human immune system.
Particularly, intake of the medication during the first days of HSC transplantation is expected to increase the engraftment of HSC, as well as the activity of these HSC into rapidly generating the panoply of blood cells. In addition, after intake of the medication by patients with weak immune systems, such as anemia, myelodysplastic syndrome or post-chemotherapy, there should be a rapid outburst of mature blood cells from HSC, thereby decreasing the risk of complications.
Hematopoietic stem cell transplantations
Conditions with weak blood cell output
Makes possible the generation of cultured cells with bona fide characteristics, as they should be:
for better performance in therapeutic applications
for better functional properties in assays
PROBLEM Any kind of cell that is taken out of its microenvironment in the organism and is placed in artificial conditions of cultivation (ouside of the organism), undergoes significant changes in its original identity. It is not surprising that the performance of cultured primary cells in therapeutics or in diagnostics is lagging, despite the use of expensive instrumentation and state-of-the-art cultivation methods.
OUR SOLUTION We have discovered a unique cell signaling pathway that is responsible for these cultivation-induced changes in primary cells. Interestingly, we are able to modulate and re-establish part of the original in vivo cellular identity using a family of chemical compounds that control this key cellular pathway, such that after treatment, the caracteristics of cultivated cells resemble closely their in vivo counterparts.
As a result of re-establishing the in vivo identity of cultivated primary cells, these are able to perform much better their biological role, be it to re-gain a fuller spectrum of their functional characteristics for expanded MSC, or even to recapitulate lost behaviour, such as for cell culture-derived megakaryocytes that now generate many more platelets (100-1500/MK) compared to their counterparts where no signature correction was achieved.
Mesenchymal stem cell cultures
Hematopoietic stem cell cultures
Muscle stem cell cultures
Pluripotent stem cell cultures
bottom of page